3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
2
Thoracic
1
Head & Neck
1
Gynecologic
1
CNS
1
Breast
1
Conditions
Brain Neoplasms
3
Glioblastoma
2
Breast Neoplasms
2
Recurrence
1
Oligodendroglioma
1
Neoplasm Metastasis
1
Lung Neoplasms
1
Gliosarcoma
1
Glioma
1
Carcinoma, Non-Small-Cell Lung
1
Astrocytoma
1
Interventions
Temozolomide
23
Bevacizumab
18
Cyclophosphamide
9
Carboplatin
7
Lomustine
6
Irinotecan
6
3-Iodobenzylguanidine
6
Topotecan
5
Radiotherapy
5
Filgrastim
5
Radiosurgery
4
Nivolumab
4
Everolimus
4
Etoposide
4
Drug Therapy
4
Busulfan
4
sonidegib
3
pembrolizumab
3
olaparib
3
fludarabine phosphate
3
fludarabine
3
cemiplimab
3
antineoplaston AS 2-1
3
antineoplaston A10
3
Vincristine
3
Thiotepa
3
Sirolimus
3
Melphalan
3
IL13-PE38
3
Antilymphocyte Serum
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recurrence
×
cabazitaxel
×
CNS
×
Clear all
NCT02166658
2018-01-23
CaBaMet
AIO-Studien-gGmbH
Phase 2
Terminated
8 enrolled